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Background: Use of multivitamins may reduce the risk of colorectal adenoma, but the duration of use needed is unclear.
Methods: We prospectively examined years of multivitamin use and risk of colorectal adenoma among 43641 women who had a
first endoscopy between 1991 and 2007 in the Nurses’ Health Study II. Use of multivitamins was assessed through biennial
questionnaires since 1989.
Results: We documented 2277 colorectal adenoma cases. Reporting multivitamin use at any time during the study period
compared with never reporting its use was associated with a reduced risk of adenoma (multivariable relative risk (RR)¼0.86, 95%
confidence interval (CI): 0.76–0.97). There was no clear trend with duration of multivitamin use: years of use compared with never
use, p4 years (RR¼0.84, 95% CI: 0.74–0.96), 5–9 years (RR¼0.89, 95% CI: 0.77, 1.02), 10–14 years (RR¼0.86, 95% CI: 0.74, 1.01),
15–19 years (RR¼0.85, 95% CI: 0.70, 1.02), and 20–26 years (RR¼0.80, 95% CI: 0.64, 1.01); (P trend¼0.87). The strongest
associations (years of use vs never user) were for size of adenoma: large (X1cm) o4 years (RR¼0.75, 95% CI: 0.58–0.96) and in
alcohol users (X1.4g per day) 20–26 years (RR¼0.67, 95% CI: 0.49–0.91).
Conclusion: Our findings suggest that use of multivitamins is associated with lower risk of colorectal adenoma, even with relatively
short duration of use.
Multivitamins contain several nutrients which are thought to affect
colorectal carcinogenesis. Vitamin D may reduce the risk of
colorectal cancer by increasing cell differentiation and apoptosis,
decreasing cell proliferation, inhibiting angiogenesis, and through
cell-cycle regulation (Holt et al, 2002; Lamprecht and Lipkin, 2003;
Chlebowski et al, 2004; Grant and Garland, 2004; Giovannucci,
2006a). Folate and vitamin B6 are thought to affect colorectal
carcinogenesis through the roles they have in DNA synthesis and
methylation. Folate influences DNA methylation through the
regeneration of methionine and functions as a coenzyme with
vitamin B6 in the synthesis of purines, thymidylate, and DNA
(Zhang et al, 2006). Deficiencies in these vitamins may result in
uracil misincorporation into DNA, causing breaks in chromosomes
and interference with the DNA repair process (Wickramasinghe
and Fida, 1994; Blount et al, 1997; Ames, 2001). Vitamin B6 is also
a cofactor for numerous physiological processes, including cell
proliferation and nitric oxide synthesis, which could reduce the risk
of colon cancer (Matsubara et al, 2003). It is also possible that other
components of multivitamins (e.g. vitamin C or E) could affect
colorectal carcinogenesis. This issue is of practical importance
because most randomized control trials on prevention of colorectal
neoplasia consider adenomas rather than cancer itself as the
endpoint. Because colorectal cancer takes longer to develop than an
adenoma, an effect of multivitamin use on adenomas might be seen
with a shorter duration of use than one on colorectal cancer, as was
seen in two older cohorts of men and women (Lee et al, 2011).
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et al, 1998; Jacobs et al, 2001; Jacobs et al, 2003; Lee et al, 2011),
but not all studies (Neuhouser et al, 2009), on the relationship
between multivitamin use and colon cancer have found that long
duration of use or long duration since first use of multivitamins
was associated with lower risk of colon cancer. Results from the
positive studies suggest a delayed effect of multivitamin use on
the risk of colorectal cancer; however, the time relation with
precursors of colorectal cancer (adenomatous polyps) is less clear
(Lee et al, 2011). To our knowledge, no research has examined the
duration of multivitamin use in relation to occurrences of
colorectal adenoma in a young cohort. We, therefore, examined
the duration of multivitamin use in relation to the occurrence of
colorectal adenomas in a cohort of young women. Our primary
endpoints were total adenoma and ‘high-risk’ adenoma (large,
any mention of villous histology or high-grade dysplasia). In
addition, we performed secondary analyses considering regions of
the colorectum as well as types of adenoma (defined by size). In
other secondary analyses, we examined whether selected char-
acteristics (family history of colorectal cancer, physical activity,
and intakes of retinol, dietary folate, and alcohol) modified the
association between duration of multivitamin use and colorectal
adenoma.
SUBJECTS AND METHODS
Study population. The Nurses’ Health Study II (NHS II) began in
1989, when 116671 female registered nurses completed a mailed
questionnaire about lifestyle factors and medical history (Colditz
and Hankinson, 2005). Every 2 years participants in the NHS II
were mailed follow-up questionnaires to update information on
possible risk factors for disease, as well as to identify newly
diagnosed illnesses. Response rates exceeded 90% for every 2-year
period. The follow up for this analysis began in 1991 when diet was
first assessed through a semi-quantitative food frequency ques-
tionnaire. Participants were aged 26–46 years at the start of
follow-up.
We excluded women if they did not complete a dietary
questionnaire in 1991 or if they had any diagnosis of cancer
(excluding nonmelanoma skin cancer), inflammatory bowel
disease, familial polyposis, or colorectal polyp before 1991. We
only included women who had their first lower gastrointestinal
endoscopic procedure (colonoscopy or sigmoidoscopy) during the
study period. After applying our exclusion criteria, 43641 women
were eligible for this analysis. This study was approved by the
Institutional Review Boards of the Harvard School of Public Health
and the Brigham and Women’s Hospital.
Ascertainment of colorectal adenoma cases and controls. The
ascertainment of adenoma cases and controls has been previously
described (Giovannucci et al,1 9 9 3 ) .B r i e f l y ,o ne a c hb i e n n i a l
questionnaire, we inquired about the indications for the
procedure; whether colon or rectal polyps had been diagnosed;
and, if so, the date of diagnosis. Women who indicated a new
diagnosis of colorectal polyp on a follow-up questionnaire were
mailed a consent form to ask for medical records. Study
investigators, who were blinded to the exposure status of the
women, reviewed the records and collected information on the
anatomic location, histological type, and size of the reported
polyps. Only those adenoma cases that were confirmed by
pathology report were considered in this analysis. Only those
w o m e ni nt h eN H SI Iw h oh a dt h e i rf i r s te n d o s c o p yp r o c e d u r e
during the study period are included in this investigation; repeat
endoscopies are not considered. Between 1991 and 2007, we
documented 2277 women with adenomas in the proximal or
distal colon or rectum, or any combination of the three locations
diagnosed during their first endoscopy. We documented 1011
proximal colon, 1107 distal colon, and 398 rectal adenomas; cases
can have adenomas counted in multiple locations. In total, 1599
women were classified as having all small (o1cm) adenomas,
556 women had one or more large (X1cm) adenoma, and 122
women had missing information on adenoma size, mainly as a
result of biopsy procedures which left the size inestimable. In
total, 1090 were classified as having low risk (small and tubular),
696 had high risk (large, any mention of villous histology or high-
grade dysplasia), and 491 women had missing information on
adenoma stage because of similar issues with biopsy procedures.
Non-cases consisted of women who did not have adenoma
detected during their first endoscopy, although they may have
had adenoma diagnosed at a later endoscopy or had hyperplastic
polyps. Two thousand one hundred and fifty-four women had
missing information on years of multivitamin use and were
excluded from analyses.
Assessment of multivitamin use and duration. At the beginning
of the NHS II study in 1989, a questionnaire was mailed to
participants to collect information on lifestyle factors, disease
status, and current use of vitamin supplement use, including the
duration of use. Current multivitamin use was additionally
assessed in the biennial questionnaires, which were administered
between 1991 and 2005. We also collected data on specific brands
and types of multivitamin supplements (Willett et al, 1985; Salvini
et al, 1989).
Total duration of multivitamin use was calculated by adding the
‘past’ years of use with ‘current’ years of use. The number of ‘past’
years was first obtained from the 1989 questionnaire, on which
participants were asked if they currently take a multivitamin and
for the duration of time they had been taking it (0–1, 2–4, 5–9, or
10þ years). If a participant answered ‘yes’ to being a current user,
but did not provide the duration of years use, she was assigned to
be missing for duration. The 10þ years’ time interval was
considered as 10 years; however, the remaining ‘past’ use time
intervals were calculated for all participants by using the midpoint
number of years for each of these intervals (0–1 was considered as
0.5 years, 2–4 was considered as 3 years, 5–9 was considered as 7
years). The ‘current’ usage years were updated from information
obtained from the current user (yes/no) question from each
biennial follow up questionnaire starting in 1991 through 2005; for
each questionnaire cycle that the participant responded ‘yes’ to
current user, we added 2 additional years onto her years of total
multivitamin use. For example, if a participant reported having
been a multivitamin user for the previous 2–4 years in 1989, we
would take the median value of this range, 3 years, for her ‘past’
usage component. If this same respondent reported being a non-
user in 1991, 1993, and 1995 but reported being a user in 1997 and
1999, her total years of ‘current’ multivitamin use from these
questionnaires would be 0þ0þ0þ2þ2 to total 4 years. Then we
would add her 3 years of reported use from 1989 and combine
them with her 4 years from 1997 and 1999 for a final estimate of
duration of multivitamin use of 7 years as of 1999.
Assessment of other covariates. Information on height, body
weight, recreational physical activity, smoking (including
number of packs of cigarettes and years smoked), aspirin use,
and region of residence to estimate solar ultraviolet radiation
were collected on biannual questionnaires. Body mass index
(BMI; kg m
 2) was calculated using height and weight. Solar
ultraviolet radiation (UV-B in Robertson–Berger meter units)
was collected from 30 photosensitive meters across the
UnitedStates and was matched to the place of residence
(Scotto et al, 1988). Dietary information was collected from
the participants using validated semi-quantitative food which
were administered during 1991, 1995, 1999, and 2003.
These questionnaires listed about 130 foods and beverages.
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they consumed a commonly used unit or portion size of each
item. Nutrient intakes were then computed by multiplying the
consumption frequency of each unit of every food by the
nutrient content of the specified portions using composition
values from the U.S. Department of Agriculture and additional
sources (Willett et al, 1985; Agriculture, 1989). Cumulative
averaging of all available dietary measures up to the start of each
2-year interval was used to obtain the most accurate representa-
tion of the women’s long-term dietary pattern.
Statistical analysis. We analysed total years of multivitamin use in
relation to the risk of colorectal adenoma for the main analysis,
and then performed separate analyses of adenomas in the proximal
colon, distal colon, and rectum. In addition, we stratified by size
and high-/low-risk pathologic features of adenomas. Large
adenomas were defined as X1cm, small as o1cm, high risk
were defined as large or any mention of villous histology or high-
grade dysplasia, and finally low risk as small and tubular.
Multivariable logistic regression models were used to calculate
odds ratios to approximate relative risks (RRs) of diagnosed
adenoma in the large bowel. To control for potential confounders,
we created one model with known non-dietary risk factors for
adenoma: age in 5-year intervals, time period of endoscopy (2-year
study period interval), reason for first endoscopy (screening vs
symptoms), family history of colorectal cancer (first-degree
relative), height (categories in inches: 39–62, 63–64, 65–66, and
67–81), BMI (quintiles), physical activity (MET- h per week in
quintiles), pack-years of smoking (quintiles of packs of cigarettes
smoked per year), aspirin use (never, past only, current use 1 day
per week, current use 2–3 days per week, current use 4–5 days per
week, and current use X6 days per week), and UV-B (Robertson–
Berger meter units in quintiles). A second model was developed
which included all of the previously mentioned non-dietary factors
as well as dietary variables that could be confounders; these
included: intake of energy-adjusted calcium (milligrams (mg) per
day in quintiles), dietary folate (from food not supplements)
(micrograms (mcg) per day in quintiles), alcohol (grams (g) per
day in categories: 0, 40t oo5, 5 to o15, and X15), unprocessed
red meat and processed meats (servings per day in quintiles). We
also performed restricted cubic spline analyses to investigate a non-
linear relationship between years of multivitamin use and risk of
colorectal adenoma.
In addition, in subgroup analyses we examined whether selected
cumulative updated characteristics (family history of colorectal
cancer, physical activity, and intakes of retinol, dietary folate, and
alcohol) modified the association between duration of multi-
vitamin use and colorectal adenoma. We used medians of selected
characteristics to create each subgroup. We tested if the association
between multivitamin use and colorectal adenoma differed by
family history by using this variable to stratify the fully adjusted
multivariable model, using years of multivitamin use as a
continuous variable, and performing a Wald test to compare the
years of multivitamin use estimates. We tested whether the
association between multivitamin use and colorectal adenoma
differed by other potential modifiers by creating an interaction
term between years of multivitamin use and these variables. We
then performed one degree of freedom likelihood ratio tests
comparing a fully adjusted multivariable model with years of
multivitamin use considered as a continuous variable with a second
model with the same variables as previously mentioned and the
interaction term.
We tested for trend after excluding non-multivitamin users and
using duration of years of multivitamin use as a continuous
variable in our multivariate logistic models. All reported P-values
are two-sided. We conducted all analyses using SAS version 9 (SAS
Institute, Inc., Cary, NC, USA).
RESULTS
Table 1 shows the age-standardized characteristics of women at
time of their first endoscopies according to categories of total years
of multivitamin use. Women who took multivitamins for the
longest duration at the time of their endoscopy, 20–26 years, were
more likely to have had a lower BMI, engaged in physical activity
for more hours per week, had fewer pack-years of smoking, have
been current or past aspirin users, and consumed more calcium,
vitamin D, and dietary folate than women with fewer years of
multivitamin use. These differences were relatively small. After
adjusting for potentially confounding variables, an inverse
association for multivitamin use and risk of colorectal adenoma
was found when compared with never users multivariable adjusted
(RR¼0.86, 95% CI: 0.76–0.97) (Table 2). The longest duration of
multivitamin use was suggestive of the largest inverse association
with the risk of colorectal adenoma (20–26 years; RR¼0.80, 95%
CI: 0.64, 1.01), although there was no significant trend with years
of use (test for linear trend among users P¼0.87) (Table 2).
In the proximal colon, the longest duration of multivitamin use
for 20–26 years was also suggestive of an inverse association with
the risk of adenoma (RRproximal¼0.76, 95% CI: 0.55–1.06), and as
with the total adenoma analysis, there was no significant linear
trend (P¼0.92). Suggestive inverse associations between adenoma
found in the distal colon and categories of duration of multi-
vitamin use were estimated with the strongest appearing in the
shortest period of time of 4 years or less (RRdistal ¼0.78, 95% CI:
0.65–0.94) (Table 2). There were suggestive inverse associations
between adenoma in the rectum and most categories of multi-
vitamin use; however, there was no clear pattern with the duration
of use (Table 2). The numbers of adenoma in the rectum are small
which may make these associations more difficult to interpret.
We evaluated the association between the use of multivitamins
and size of adenomas. The magnitude of the association with
multivitamin use for 4 years or less was stronger for large adenoma
compared with small adenoma (RRlarge¼ 0.75, 95% CI: 0.58–0.96),
but there was no trend with increasing use ( Ptrend¼0.98);
(RRsmall¼0.86, 95% CI: 0.73, 1.01; Ptrend¼0.35) (Table 3). When
we evaluated ever compared with never multivitamin users, there
was a significant inverse association with large adenomas and
marginal with small adenomas (RRlarge¼0.79, 95% CI: 0.63, 0.98;
RRsmall¼0.88, 95% CI: 0.76, 1.01) (Table 3).
The association of multivitamin use for high-risk adenoma
appeared strongest in the shortest time period of 4 years or less
(RRhigh risk¼0.77, 95% CI: 0.61, 0.97); conversely for low-risk
adenoma, multivitamin use only became significant in the longest
years of use category (RR 20–26 yearslow risk¼0.69, 95% CI: 0.50,
0.95; Ptrend¼0.40) (Table 3).
No significant difference in the relationship between multi-
vitamin use and risk of colorectal adenoma was found when
analyses were stratified by family history of colorectal cancer
(Pfamily history¼0.98). Associations between multivitamin use and
risk of adenoma did not also differ by levels of physical activity
(Pphysical activity¼0.24), intake of retinol (Pretinol¼0.51), dietary
folate, and alcohol (Pfolate¼0.61, Palcohol¼0.21) (Table 4).
DISCUSSION
In this large prospective study of women, 20 years or more of
multivitamin use was suggestive of a 20% lower risk of colorectal
adenoma. There was also suggestion of lower risk of adenoma after
a longer latency period in the proximal colon and with low-risk
adenoma. A short period of 4 years or less of multivitamin use was
associated with a reduced risk with adenoma in the distal colon as
well as with large (X1cm) and high risk (large or villous histology
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strong association between multivitamin use and reduced risk of
colorectal adenoma among those who drank alcohol.
Most studies of cancer observed a long latency period of
multivitamin use before observing lower colon cancer incidence or
mortality (Neuhouser et al, 2009; Park et al, 2010; Lee et al, 2011;
Gaziano et al, 2012). A pooled analysis of 13 cohort studies found
that multivitamin use after 7–20 years of follow-up was associated
with a reduced risk of colon cancer (RR 0.88, 95% 0.81–0.96) (Park
et al, 2010). However, a recent randomized controlled trial of
multivitamin use followed men for an average of 11 years and did
not find an association with colorectal cancer (multivitamin vs
placebo groups, 1.2 vs 1.4 events, per 1000 person-years; HR, 0.89;
95% CI, 0.68–1.17; P¼0.39), although the magnitude of the RR
was compatible with the observational data (Gaziano et al, 2012). A
shorter duration of use, median of 8 years, was not found to be
associated with the risk of colorectal cancer in the Women’s Health
Initiative cohorts (RR 0.99, 95% CI 0.88–1.11) (Neuhouser et al,
2009). Last, an investigation using the NHS and HPFS cohorts
found that duration of multivitamin use appeared to be associated
with colorectal cancer only after 16 years or longer of use (RR16–19
years¼0.71, 95% CI: 0.53, 0.96; RR420 years¼0.77, 95% CI: 0.64,
0.94) (Lee et al, 2011). That same study also examined associations
between the duration of multivitamin use and the risk colorectal
adenoma and found a shorter period of use was associated with a
27% lower risk after at least 6–9 years (Lee et al, 2011). On the
other hand, a recent study of cancer mortality which pooled 70000
individuals from randomized control trials found no association
between multivitamin use and death from any cancer (RR: 0.96;
95% CI: 0.88, 1.04) (Macpherson et al, 2013).
The findings from our study support those of the studies in
colorectal cancer and suggest that compounds in multivitamins
may have long-term effects on the risk of adenoma. We did not
find a trend with years of usage, only a suggestion in the longest
time period of usage. The short temporal relationship between
multivitamin use and colorectal adenoma reported from the NHS
and HPFS cohorts (Lee et al, 2011) is most similar to what we
found in NHS II with regard to risk of large and high-risk
adenoma. We may see a pattern of long-term effects of
multivitamins to reduce overall risk of adenoma and low-risk
adenoma and short-term effects for high-risk adenoma because of
the multiple factors acting within a multivitamin. For example,
folic acid in multivitamins could be protective early and reduce the
risk of high-risk adenoma, but it may take time to observe this
effect for all adenomas, especially low-risk adenoma. However,
there could be another factor, such as vitamin D, which could help
prevent the progression of small into large adenomas (Wei et al,
2008).
Possible pathways through which folic acid in multivitamins
could influence colorectal adenoma occurrence includes its crucial
role in one-carbon metabolism, that is, DNA synthesis, methyla-
tion, and repair (Giovannucci, 2002; McGlynn et al, 2013).
Chromosomal breakage and uracil misincorporation into DNA
can occur with a deficiency of folate, and folic acid supplementa-
tion can reverse this (Blount et al, 1997; Ames, 2001). 1973 was the
first year that it was permissible to add up to 400mg of folic acid to
vitamin supplements in the United States (US Food and Drug
Administration, 1973); therefore, our study encompassed a period
when most multivitamins contained 400mg of folic acid. In a
pooled analysis of three randomized trials, participants who took
folic acid supplementation (0.5 or 1.0mg per day) had no
reduction in risk of recurrent adenoma after up to 3.5 years of
follow-up (Figueiredo et al, 2011). In addition, animal models have
shown that folate inhibits only early stages of colorectal
carcinogenesis (Song, 2000). When colorectal neoplasms are
already present, excess folate may act as a short-term tumour
Table 1. Age-standardized characteristics according to total years of multivitamin use at the time of first endoscopy in women
Years of multivitamin use at the time of endoscopy
None 1–4 5–9 10–14 15–19 20–26
Participants (n) 6930 11277 9789 7260 3763 2384
Mean age (years) 45.9 46.3 48.2 48.3 49.1 50.9
Family history of colorectal cancer (%) 7.5 6.5 5.8 5.4 5.5 4.5
Reason for endoscopy is screening (%) 68.5 69.2 70.0 70.0 69.3 72.0
Height (inches) 64.8 64.8 65.0 65.0 65.0 63.3
Body mass index (kgm
 2) 26.9 27.2 26.9 26.5 26.2 25.1
Physical activity (METs hours per week) 16.8 17.4 18.9 20.0 20.8 22.1
Smoking (pack-years) 9.0 8.6 7.9 8.1 7.6 6.5
Aspirin use (%)
Never use 53.8 50.0 43.3 41.8 38.5 32.9
Past use 24.2 26.6 28.1 29.7 32.0 33.2
Current use (X1 per week) 22.0 23.4 28.6 28.5 29.5 33.9
Calcium (mg per day) 922 1035 1156 1260 1315 1359
Vitamin D (IUs per day) 236 322 411 488 523 546
Red meat (servings per day) 0.94 1.05 1.14 1.15 1.27 1.43
Processed meat (servings per day) 0.17 0.17 0.16 0.16 0.15 0.14
Alcohol (g per day) 3.6 3.7 3.8 3.9 4.1 3.9
Dietary folate (mcg per day)
a 306 314 322 329 330 333
UV-B flux (Robertson–Berger meter units) 124 124 125 126 127 123
Except for the data on mean age all data shown are standardized to the age distribution of the cohort.
aFolate from food excluding supplemental sources.
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reactions (Kim, 2003, 2007). However, we did not observe any
adverse effect of multivitamin use. This is especially noteworthy
considering our study population was consuming even greater
amounts of folate beyond those from multivitamins during this
study period as folate fortification of US breads, cereals, and other
grains began in 1997 (US Food and Drug Administration, 1996). In
addition, we found a stronger inverse association between
Table 2. RR of colorectal adenoma among women in the NHS II, 1991–2005, by total years of multivitamin use
RR and (95% CI) by category
0 years 1–4 years 5–9 years 10–14 years 15–19 years 20–26 years P trend
a Ever/never users
Adenoma
b
No. of cases/no. of controls 413/6541 581/10717 559/9247 400/6871 200/3569 124/2265 1864/32669/413/6541
Age-adjusted RR
c 1.00 0.82 (0.72–0.93) 0.83 (0.73–0.95) 0.79 (0.68–0.91) 0.77 (0.64–0.91) 0.69 (0.56–0.86) 0.10 0.80 (0.72–0.90)
Multivariable RR
d 1.00 0.83 (0.72–0.94) 0.86 (0.75–0.98) 0.82 (0.71–0.95) 0.80 (0.67–0.96) 0.75 (0.61–0.94) 0.35 0.83 (0.74–0.93)
Multivariable RR
e 1.00 0.84 (0.74–0.96) 0.89 (0.77–1.02) 0.86 (0.74–1.01) 0.85 (0.70–1.02) 0.80 (0.64–1.01) 0.87 0.86 (0.76–0.97)
Proximal colon
No. of cases/no. of controls 164/6541 247/10717 246/9247 190/6871 106/2158 58/2265 847/32669/164/6541
Age-adjusted RR
c 1.00 0.84 (0.69–1.03) 0.83 (0.68–1.02) 0.85 (0.69–1.05) 0.90 (0.70–1.16) 0.68 (0.50–0.92) 0.34 0.84 (0.70–1.00)
Multivariable RR
d 1.00 0.85 (0.69–1.04) 0.86 (0.70–1.06) 0.89 (0.71–1.11) 0.93 (0.72–1.20) 0.73 (0.53–1.00) 0.71 0.86 (0.72–1.03)
Multivariable RR
e 1.00 0.86 (0.70–1.05) 0.88 (0.71–1.08) 0.91 (0.73–1.14) 0.96 (0.74–1.25) 0.76 (0.55–1.06) 0.92 0.88 (0.73–1.05)
Distal colon
No. of cases/no. of controls 219/6541 278/10717 284/9247 179/6871 90/2158 57/2265 888/32669/219/6541
Age-adjusted RR
c 1.00 0.75 (0.62–0.90) 0.85 (0.71–1.02) 0.72 (0.58–0.88) 0.70 (0.54–0.90) 0.68 (0.50–0.92) 0.31 0.76 (0.65–0.89)
Multivariable RR
d 1.00 0.77 (0.64–0.92) 0.88 (0.73–1.05) 0.74 (0.60–0.91) 0.75 (0.58–0.97) 0.75 (0.55–1.02) 0.62 0.79 (0.67–0.92)
Multivariable RR
e 1.00 0.78 (0.65–0.94) 0.92 (0.76–1.11) 0.79 (0.64–0.98) 0.81 (0.62–1.06) 0.83 (0.60–1.14) 0.66 0.83 (0.70–0.97)
Rectum
No. of cases/no. of controls 70/6541 112/10717 88/9247 76/6871 28/2158 24/2265 328/32669/70/6541
Age-adjusted RR
c 1.00 0.94 (0.70–1.28) 0.80 (0.58–1.10) 0.93 (0.66–1.30) 0.67 (0.43–1.05) 0.85 (0.52–1.37) 0.41 0.87 (0.66–1.13)
Multivariable RR
d 1.00 0.96 (0.70–1.30) 0.84 (0.61–1.17) 1.00 (0.71–1.41) 0.73 (0.46–1.15) 0.96 (0.59–1.57) 0.77 0.91 (0.70–1.19)
Multivariable RR
e 1.00 0.96 (0.71–1.30) 0.85 (0.62–1.18) 1.01 (0.72–1.42) 0.73 (0.46–1.15) 0.97 (0.60–1.59) 0.76 0.92 (0.70–1.21)
aCalculated excluding non-multivitamin users and using years of multivitamin use as a continuous variable.
bAdenoma found in proximal and/or distal colon and/or rectum.
cOdds ratio and 95% CI from age, time-period-adjusted logistic regression.
dOdds ratio and 95% CI from model above (c) additionally controlling for non-dietary covariates: family history of colorectal cancer, height, reason for endoscopy, BMI, physical activity, pack
years of smoking, aspirin use, and UV-B flux.
eOdds ratio and 95% CI from model above (d) additionally controlling for intakes of energy adjusted calcium, folate from food, alcohol, red meat, and processed meats.
Table 3. Relative risk of large (X1cm) and small (o1cm), high-risk (large or villous histology or high grade dysplasia) and low-risk (small and tubular)
colorectal adenoma among women in the Nurses’ Health Study II, 1991–2005, by total years of multivitamin use
RR and (95% CI) by category
0 years 1–4 years 5–9 years 10–14 years 15–19 years 20–26 years P trend
a Ever/never users
Adenoma
b
Large
No. of cases/no. of controls 119/6541 139/10717 135/9247 97/6871 43/3569 23/2265 556/32669/119/6541
Multivariable RR
c 1.00 0.75 (0.58–0.96) 0.84 (0.65–1.10) 0.86 (0.64–1.15) 0.73 (0.50–1.07) 0.67 (0.42–1.09) 0.98 0.79 (0.63–0.98)
Small
No. of cases/no. of controls 274/6541 404/10717 400/9247 277/6871 149/3569 95/2265 1599/32669/274/6541
Multivariable RR
c 1.00 0.86 (0.73–1.01) 0.92 (0.78–1.09) 0.85 (0.71–1.02) 0.94 (0.73–1.12) 0.85 (0.66–1.10) 0.35 0.88 (0.76–1.01)
High risk
No. of cases/no. of controls 142/6729 171/10990 164/9531 121/7064 62/3665 21/2321 696/33571/142/6729
Multivariable RR
c 1.00 0.77 (0.61–0.97) 0.87 (0.68–1.10) 0.91 (0.70–1.19) 0.91 (0.70–1.25) 0.91 (0.61–1.35) 0.16 0.84 (0.69–1.02)
Low risk
No. of cases/no. of controls 188/6683 273/10888 284/9411 193/6992 96/3631 56/2301 1090/33223/188/6683
Multivariable RR
c 1.00 0.83 (0.69–1.01) 0.91 (0.74–1.10) 0.82 (0.66–1.02) 0.80 (0.61–1.04) 0.69 (0.50–0.95) 0.40 0.84 (0.71–1.00)
aCalculated excluding non-multivitamin users using years of multivitamin use as a continuous variable.
bAdenoma found in proximal and/or distal colon and/or rectum.
cOdds ratio and 95% CI from logistic regression adjusted for covariates mentioned in Table 2.
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consumed X1.4g per day of alcohol. Alcohol is an established
folate antagonist and there is consistent evidence that a combina-
tion of alcohol consumption and low folate intakes are associated
with an increased risk of colorectal cancer (Giovannucci and
Willett, 1994; Giovannucci et al, 1995; La Vecchia et al, 2002). It
would follow that the folic acid in multivitamins would be
particularly important in colorectal adenoma incidence reduction
among those in a possible depleted state due to alcohol
consumption.
Other important components in multivitamins include
vitamin B6, which is involved in DNA synthesis and methylation
(Zhang et al, 2006). Vitamin D is an usual component of
multivitamins and is thought to accelerate apoptosis in colorectal
mucosa and may also reduce risk of colorectal cancer through its
role in cell differentiation and proliferation (Lamprecht and Lipkin,
2001; Holt et al, 2002; Grant and Garland, 2004; Harris and Go,
2004; Giovannucci, 2006b). Lastly, vitamins C, E, and beta-
carotene found in multivitamins have numerous biological
activities that are thought to be important in cancer prevention
such as trapping free radicals, assisting in cell communication, and
activating the immune system (van Poppel and van den Berg,
1997). Because most multivitamins contain several of these
vitamins, it is not possible to separate their independent effects.
To our knowledge, this is the first prospective study to
investigate the relation of long-term use of multivitamins on risk
of colorectal adenoma in a cohort of younger women. Strengths of
our study include its prospective design, large sample size, a high
follow-up response rate, use of first endoscopy procedure, repeated
assessments of multivitamin use, and detailed repeated data on
many potential confounders. These factors reduce the chance that
bias or residual confounding influenced our results.
‘Health conscious’ behaviours such as physical activity, aspirin
use, and low pack years of cigarette smoking were all slightly more
prevalent among participants with the longest duration of multi-
vitamin use. These lifestyle factors were controlled for in this study;
yet it is possible that there was some residual confounding due to
errors in measurement of these covariates. However, we found only
small differences in magnitude of associations between the age-
adjusted analyses and the multivariate analyses that controlled for
these ‘health conscious’ traits suggesting potential residual
confounding unlikely explained our results.
One limitation of our study is that duration of multivitamin use
was assessed by questionnaires which are likely to result in some
misclassification of exposure. However, misclassification of expo-
sure should not be associated with the outcome because our study
design was prospective. Therefore, misclassification of exposure
would tend to bias the results towards the null. Another limitation
is that the study was comprised of young women only; therefore,
the results may not be generalisable to older women or to men. In
addition, because this is an observational study we can only assess
the associations between multivitamin use and colorectal adenoma
occurrence and not causal relationships.
In conclusion, our results suggest that 20 years or more of
multivitamin use is associated with reduced risk of colorectal
adenoma in young women; with shorter durations needed for large
and high-risk adenoma. Further studies are needed to better define
the duration of use that is required before potential protective
effects of multivitamin use can be detected, and whether timing of
exposure or duration of exposure is the critical factor in the
reduction of risks. The specific components of multivitamins that
may reduce the risk need to be identified. This information may be
relevant to the conduct of randomized control trials with
adenomas as the endpoint.
ACKNOWLEDGEMENTS
We appreciate the contributions of Gary Chase, Karen Corsano,
and Scott Smith for their expert help. This work was supported
by research grants: R01 CA50385; CA55075; R02 CA125837/
CA151993 from the National Institutes of Health.
REFERENCES
AGRICULTURE, U. S. D. O (1989) Composition of foods-raw, processed, and
prepared, 1963-1988 Agricultural Handbook No. 8 Series. Washington,
DC: Department of Agriculture, US Gov Pr Office.
Table 4. Relative risk of colorectal adenoma among women in the NHS II,
1991–2007, by 20–26 years vs never use and ever vs never use of
multivitamins stratified by family history, physical activity and intakes of
retinol, folate from food (not supplements), and alcohol
RR and (95% CI)
Adenoma
a 20–26 years/
never use Ever/never use
Family history (yes)
No. of cases/no. of controls 16/150/108/1188 358/4595/108/1188
Multivariable RR
b 1.13 (0.62–2.06) 0.88 (0.69–1.12)
Family history (no)
No. of cases/no. of controls 108/2115/305/5353 1506/28074 / 305/5353
Multivariable RR
b 0.77 (0.60–0.98) 0.86 (0.75–0.99)
High physical activity (X14.5 METs hours per week)
No. of cases/no. of controls 57/1099/132/2303 713/13491/132/2303
Multivariable RR
b 0.72 (0.52–0.99) 0.76 (0.63–0.92)
Low physical activity (o14.5 METs hours per week)
No. of cases/no. of controls 66/1162/280/4215 1148/19120/280/4215
Multivariable RR
b 0.84 (0.60–1.16) 0.92 (0.79–1.07)
High retinol(X2913 IU)
No. of cases/ no. of controls 113/1992/44/830 1052/18821/44/830
Multivariable RR
b 1.00 (0.69–1.47) 1.00 (0.73–1.38)
Low retinol (o2913 IU)
No. of cases/no. of controls 11/273/369/5711 812/13848/369/5711
Multivariable RR
b 0.54 (0.29–1.00) 0.82 (0.71–0.94)
High dietary folate ( X314mcg per day)
No. of cases/no. of controls 86/1476/171/2637 937/16989/171/2637
Multivariable RR
b 0.85 (0.63–1.02) 0.80 (0.67–0.96)
Low dietary folate (o314mcg per day)
No. of cases/no. of controls 38/789/242/3904 927/15680/242/3904
Multivariable RR
b 0.85 (0.63–1.14) 0.90 (0.77–1.06)
X1.4g per day alcohol
No. of cases/no. of controls 63/1261/199/2989 979/16677/199/2989
Multivariable RR
b 0.67 (0.49–0.91) 0.82 (0.70–0.98)
o1.4g per day alcohol
No. of cases/no. of controls 61/1004/214/3552 885/15992/214/3552
Multivariable RR
b 1.00 (0.73–1.38) 0.90 (0.76–1.06)
aAdenoma found in proximal and/or distal colon and/or rectum.
bOdds ratio and 95% CI from logistic regression adjusted for: covariates mentioned in
Table 2.
Models that are stratified by family history, physical activity, and intakes of retinol, folate,
and alcohol do not adjust for these stratified variables in their model. Categories were
determined by median values.
Tests for effect modification 26–20/0 years use: Pfamily history ¼0.98; Pphyical activity¼0.24;
Pretinol¼ 0.51; PFolate¼0.61; PAlcohol¼0.21.
BRITISH JOURNAL OF CANCER Multivitamin use and colorectal adenoma
254 www.bjcancer.com|DOI:10.1038/bjc.2013.664Ames BN (2001) DNA damage from micronutrient deficiencies is likely to be
a major cause of cancer. Mutat Res 475: 7–20.
Blount BC, Mack MM, Wehr CM, Macgregor JT, Hiatt RA, Wang G,
Wickramasinghe SN, Everson RB, Ames BN (1997) Folate deficiency
causes uracil misincorporation into human DNA and chromosome
breakage: implications for cancer and neuronal damage. Proc Natl Acad
Sci USA 94: 3290–3295.
Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J,
Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C,
Adams-Campbell LL, White E (2004) Estrogen plus progestin
and colorectal cancer in postmenopausal women. N Engl J Med 350:
991–1004.
Colditz GA, Hankinson SE (2005) The Nurses’ Health Study: lifestyle and
health among women. Nat Rev Cancer 5: 388–396.
Figueiredo JC, Mott LA, Giovannucci E, Wu K, Cole B, Grainge MJ, Logan RF,
Baron JA (2011) Folic acid and prevention of colorectal adenomas: a
combined analysis of randomized clinical trials. Int J Cancer 129:
192–203.
Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, Macfadyen J,
Schvartz M, Manson JE, Glynn RJ, Buring JE (2012) Multivitamins in the
prevention of cancer in men: the Physicians’ Health Study II randomized
controlled trial. JAMA 308: 1871–1880.
Giovannucci E (2002) Epidemiologic studies of folate and colorectal neoplasia:
a review. J Nutr 132: 2350S–2355S.
Giovannucci E (2006a) The epidemiology of vitamin D and colorectal cancer:
recent findings. Curr Opin Gastroenterol 22: 24–29.
Giovannucci E (2006b) The epidemiology of vitamin D and colorectal cancer:
recent findings. Curr Opin Gastroenterol 22: 24–29.
Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC
(1995) Alcohol, low-methionine–low-folate diets, and risk of colon cancer
in men. J Natl Cancer Inst 87: 265–273.
Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA,
Speizer FE, Willett WC (1998) Multivitamin use, folate, and colon
cancer in women in the Nurses’ Health Study. Ann Intern Med 129:
517–524.
Giovannucci E, Stampfer MJ, Colditz GA, Rimm EB, Trichopoulos D, Rosner BA,
Speizer FE, Willett WC (1993) Folate, methionine, and alcohol intake and risk
of colorectal adenoma. JN a t lC a n c e rI n s t85: 875–884.
Giovannucci E, Willett WC (1994) Dietary factors and risk of colon cancer.
Ann Med 26: 443–452.
Grant WB, Garland CF (2004) A critical review of studies on vitamin D in
relation to colorectal cancer. Nutr Cancer 48: 115–123.
Harris DM, Go VL (2004) Vitamin D and colon carcinogenesis. J Nutr 134:
3463S–3471S.
Holt PR, Arber N, Halmos B, Forde K, Kissileff H, Mcglynn KA, Moss SF,
Kurihara N, Fan K, Yang K, Lipkin M (2002) Colonic epithelial cell
proliferation decreases with increasing levels of serum 25-hydroxy vitamin
D. Cancer Epidemiol Biomarkers Prev 11: 113–119.
Jacobs EJ, Connell CJ, Chao A, Mccullough ML, Rodriguez C, Thun MJ,
Calle EE (2003) Multivitamin use and colorectal cancer incidence in a US
cohort: does timing matter? Am J Epidemiol 158: 621–628.
Jacobs EJ, Connell CJ, Patel AV, CHAO A, Rodriguez C, Seymour J,
Mccullough ML, Calle EE, Thun MJ (2001) Multivitamin use and colon
cancer mortality in the Cancer Prevention Study II cohort (United States).
Cancer Causes Control 12: 927–934.
Kim YI (2003) Role of folate in colon cancer development and progression.
J Nutr 133: 3731S–3739S.
Kim YI (2007) Folate and colorectal cancer: an evidence-based critical review.
Mol Nutr Food Res 51: 267–292.
LA Vecchia C, Negri E, Pelucchi C, Franceschi S (2002) Dietary folate and
colorectal cancer. Int J Cancer 102: 545–547.
Lamprecht SA, Lipkin M (2001) Cellular mechanisms of calcium and
vitamin D in the inhibition of colorectal carcinogenesis. Ann N Y Acad Sci
952: 73–87.
Lamprecht SA, Lipkin M (2003) Chemoprevention of colon cancer by
calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 3:
601–614.
Lee JE, Willett WC, Fuchs CS, Smith-Warner SA, Wu K, Ma J, Giovannucci E
(2011) Folate intake and risk of colorectal cancer and adenoma:
modification by time. Am J Clin Nutr 93: 817–825.
Macpherson H, Pipingas A, Pase MP (2013) Multivitamin-multimineral
supplementation and mortality: a meta-analysis of randomized controlled
trials. Am J Clin Nutr 97: 437–444.
Matsubara K, Komatsu S, Oka T, Kato N (2003) Vitamin B6-mediated
suppression of colon tumorigenesis, cell proliferation, and angiogenesis
(review). J Nutr Biochem 14: 246–250.
Mcglynn AP, Wasson GR, O’reilly SL, Mcnulty H, Downes CS, Chang CK,
Hoey L, Molloy AM, Ward M, Strain JJ, Mckerr G, Weir DG, Scott JM
(2013) Low colonocyte folate is associated with uracil misincorporation
and global DNA hypomethylation in human colorectum. J Nutr 143:
27–33.
Neuhouser ML, Wassertheil-Smoller S, Thomson C, Aragaki A, Anderson GL,
Manson JE, Patterson RE, Rohan TE, Van Horn L, Shikany JM,
Thomas A, Lacroix A, Prentice RL (2009) Multivitamin use and risk of
cancer and cardiovascular disease in the Women’s Health Initiative
cohorts. Arch Intern Med 169: 294–304.
Park Y, Spiegelman D, Hunter DJ, Albanes D, Bergkvist L, Buring JE,
Freudenheim JL, Giovannucci E, Goldbohm RA, Harnack L, Kato I,
Krogh V, Leitzmann MF, Limburg PJ, Marshall JR, Mccullough ML,
Miller AB, Rohan TE, Schatzkin A, Shore R, Sieri S, Stampfer MJ,
Virtamo J, Weijenberg M, Willett WC, Wolk A, Zhang SM, Smith-Warner
SA (2010) Intakes of vitamins A, C, and E and use of multiple vitamin
supplements and risk of colon cancer: a pooled analysis of prospective
cohort studies. Cancer Causes Control 21: 1745–1757.
Salvini S, Hunter D, Sampson L, Stampfer M, Colditz G, Willett W (1989)
Food-based validation of a dietary questionnaire: the effects of
week-to-week variation in food consumption. Intl J Epidemiol 18:
858–867.
Scotto J, Cotton G, Urbach F, Berger D, Fears T (1988) Biologically effective
ultraviolet radiation: surface measurements in the United States, 1974 to
1985. Science 239: 762–764.
Song J, Sohn KJ, Ash C, Gallinger S, Kim YI (2000) Chemopreventive effects
of dietary folate on intestinal polyps in Apcþ/-Msh2-/-mice. Cancer Res
60: 191–199.
US Food and Drug Administration (1973) Statement of general policy or
interpretation. Subchapter B – food and food products, part 121 – food
additives. Federal Register 38: 20725–20726.
US Food and Drug Administration (1996) Food standards: amendment of
standards of identity for enriched grain products to require addition of
folic acid. Federal Register 61: 8781–8797.
Van Poppel G, Van Den Berg H (1997) Vitamins and cancer. Cancer Lett 114:
195–202.
Wei MY, Garland CF, Gorham ED, Mohr SB, Giovannucci E (2008) Vitamin
D and prevention of colorectal adenoma: a meta-analysis. Cancer
Epidemiol Biomarkers Prev 17: 2958–2969.
White E, Shannon JS, Patterson RE (1997) Relationship between vitamin and
calcium supplement use and colon cancer. Cancer Epidemiol Biomarkers
Prev 6: 769–774.
Wickramasinghe SN, Fida S (1994) Bone marrow cells from vitamin
B12- and folate-deficient patients misincorporate uracil into DNA.
Blood 83: 1656–1661.
W i l l e t tW C ,S a m p s o nL ,S t a m p f e rM J ,R o s n e rB ,B a i nC ,W i t s c h iJ ,H e n n e k e n sC H ,
Speizer FE (1985) Reproducibility and validity of a semiquantitative food
frequency questionnaire. Am J Epidemiol 122: 51–65.
Zhang SM, Moore SC, Lin J, Cook NR, Manson JE, Lee IM, Buring JE (2006)
Folate, vitamin B6, multivitamin supplements, and colorectal cancer risk
in women. Am J Epidemiol 163: 108–115.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 3.0 Unported License.
Multivitamin use and colorectal adenoma BRITISH JOURNAL OF CANCER
www.bjcancer.com|DOI:10.1038/bjc.2013.664 255